Amdocs Q4 Earnings Surpass Estimates, Revenues Decline Y/Y

12.11.25 13:04 Uhr

Werte in diesem Artikel
Aktien

65,16 EUR -0,58 EUR -0,88%

Amdocs Limited DOX reported better-than-expected fourth-quarter fiscal 2025 results. The company posted non-GAAP earnings of $1.83 per share, which came above the midpoint of the management’s guidance of $1.79-$1.85 and increased 7.6% year over year. The figure also exceeded the Zacks Consensus Estimate of $1.82.In the trailing four quarters, DOX’s earnings outpaced the Zacks Consensus Estimate thrice while matching once, with an average surprise of 1.6%.Amdocs’ fourth-quarter revenues of $1.15 billion surpassed the consensus mark of $1.14 billion. However, compared with the year-ago quarter, revenues were down 9% on a reported basis due to the phase-out of certain business activities. Excluding the effect of phase-out business activities, revenues were up 2.8% year over year in pro forma constant currency.Amdocs Limited Price, Consensus and EPS Surprise Amdocs Limited price-consensus-eps-surprise-chart | Amdocs Limited QuoteAmdocs’ Q4 DetailsAmdocs reported a decline in revenues across North America, Europe and the Rest of the World (RoW). North America reported revenues of $762 million (66% of total revenues), which decreased 8.8% year over year. RoW revenues (18% of total revenues) dropped 5% year over year to $208 million.Europe revenues (16% of total revenues) of $180 million decreased 0.8% year over year. Our model estimates for North America, RoW and Europe were pinned at $743.4 million, $221.2 million and $176.7 million, respectively.Managed services revenues rose 3.7% year over year to $748.3 million. The company ended the fourth quarter of fiscal 2025 with a 12-month backlog of $4.19 billion, up $40 million sequentially. Our model estimates for managed services revenues and backlog were pegged at $731.5 million and $4.07 billion, respectively.The non-GAAP operating income increased 5% year over year to $248.1 million, while the operating margin expanded 290 basis points (bps) to 21.6%.Amdocs’ Balance Sheet & Cash FlowAmdocs had cash and short-term investments of $325 million as of Sept. 30, 2025 compared with $342.5 million as of June 30, 2025. Long-term debt was $646.9 million as of Sept. 30, 2025, almost flat to the June 30, 2025 level of $646.7 million.During the fourth quarter, it generated an operating cash flow of $229.8 million and a free cash flow of $198.6 million. In full fiscal 2025, it generated operating cash flow and free cash flow of $749.1 million and $645.1 million, respectively.Amdocs Initiates Guidance for Q1 & FY2026Amdocs initiated guidance for the first quarter and fiscal 2026. For the first quarter, the company expects revenues to be in the band of $1.135-$1.175 billion (midpoint $1.155 billion). The Zacks Consensus Estimate for revenues is pegged at $1.14 billion, suggesting a year-over-year increase of 3%.Amdocs expects non-GAAP earnings per share to be between $1.73 and $1.79. The Zacks Consensus Estimate for earnings is pegged at $1.86 per share, indicating a year-over-year rise of 12%.For fiscal 2026, Amdocs expects revenues to grow in the 1.7-5.7% range. The Zacks Consensus Estimate for revenues is pegged at $4.7 billion, suggesting a year-over-year increase of 3.8%.The on-GAAP operating margin is anticipated to be in the range of 21.3-21.9% for fiscal 2026. Non-GAAP earnings per share are expected to grow in the band of 4-8%. The Zacks Consensus Estimate for earnings is pegged at $7.60 per share, indicating a year-over-year rise of 8.9%.The company expects free cash flow between $710 million and $730 million.DOX’s Zacks Rank and Stocks to ConsiderCurrently, Amdocs carries a Zacks Rank #3 (Hold).Reddit Inc. RDDT, Amphenol APH and DocuSign DOCU are some better-ranked stocks that investors can consider in the Zacks Computer and Technology sector. Reddit and Amphenol each sport a Zacks Rank #1 (Strong Buy) at present, while DocuSign carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for Reddit’s full-year 2025 earnings is pegged at $2.35 per share, revised upward by 23.7% over the past 30 days and suggests a year-over-year increase of 170.6%. Reddit shares have soared 27.4% year to date.The Zacks Consensus Estimate for Amphenol’s full-year 2025 earnings has been revised upward to $3.22 per share from $3.03 per share 30 days ago, implying 70.4% year-over-year growth. Amphenol shares have surged 106.6% year to date.The Zacks Consensus Estimate for DocuSign’s fiscal 2026 earnings has moved northward by 2 cents over the past 60 days to $3.69 per share, calling for an increase of 3.9% year over year. DocuSign shares have plunged 23.4% year to date.Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amphenol Corporation (APH): Free Stock Analysis Report Amdocs Limited (DOX): Free Stock Analysis Report Docusign Inc. (DOCU): Free Stock Analysis Report Reddit Inc. (RDDT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Amdocs

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Amdocs

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Amdocs LtdShs

Wer­bung

Analysen zu Amdocs LtdShs

DatumRatingAnalyst
31.01.2018Amdocs BuyStifel, Nicolaus & Co., Inc.
12.11.2015Amdocs Equal WeightBarclays Capital
11.11.2015Amdocs BuyStifel, Nicolaus & Co., Inc.
10.09.2015Amdocs OutperformOppenheimer & Co. Inc.
30.07.2015Amdocs BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
31.01.2018Amdocs BuyStifel, Nicolaus & Co., Inc.
11.11.2015Amdocs BuyStifel, Nicolaus & Co., Inc.
10.09.2015Amdocs OutperformOppenheimer & Co. Inc.
30.07.2015Amdocs BuyStifel, Nicolaus & Co., Inc.
19.03.2015Amdocs OutperformOppenheimer & Co. Inc.
DatumRatingAnalyst
12.11.2015Amdocs Equal WeightBarclays Capital
14.01.2011Amdocs neutralGoldman Sachs Group Inc.
22.07.2010Amdocs neutralWedbush Morgan Securities Inc.
19.07.2010Amdocs equal-weightBarclays Capital
23.04.2010Amdocs "hold"Kaufman Bros., LP
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Amdocs LtdShs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen